


# NexoBrid®

Disruptive Bioactive Therapy  
for Burn Care



## Eschar Removal

### Critical First Step in Burn Care



Prevents infection and sepsis | Stops deterioration and scarring | Tissue visible for medical evaluation

## Surgical SOC

### Traumatic, Non-Selective

Loss of healthy tissue and blood | Challenging in delicate areas | Requires surgical team, operating room



## NexoBrid: Emergent SOC

### Rapid, Effective and Selective



Simple Topical Application | Reduces Blood Loss | Preserves Viable Tissue



BEFORE



AFTER

## Highlights

- Sterile mixture of proteolytic enzymes
- Globally approved for eschar removal in burn patients of all ages in 40+ countries
- 13K+ patients treated to-date
- Topical application at bedside
- Reduces need for surgery, blood loss
- Validated & commercialized
- Improves patient outcomes
- Removes eschar within 4 hours
- Enables visual medical assessment
- Extensive government support: \$130M+ received from BARDA & DoD
- Commercially available in US by Vericel